[en] The text of a brief talk given before the Tenth LAMPF Users Meeting is presented. Progress made at the Clinton P. Anderson Meson Physics Facility is reported, and the schedule for current upgrading and typical operating cost increases are given

[en] A discussion is presented of biomedical applications of pion-producing accelerators in a number of areas, but with emphasis on pion therapy for treatment of solid, non-metastasized malignancies. The problem of cancer management is described from the standpoint of the physicist, magnitude of the problem, and its social and economic impact. Barriers to successful treatment are identified, mainly with regard to radiation therapy. The properties and characteristics of π mesons, first postulated on purely theoretical grounds by H. Yukawa are described. It is shown how they can be used to treat human cancer and why they appear to have dramatic advantages over conventional forms of radiation by virtue of the fact that they permit localization of energy deposition, preferentially, in the tumor volume. The Clinton P. Anderson Meson Physics Facility (LAMPF), and its operating characteristics, are briefly described, with emphasis on the biomedical channel. The design of a relatively inexpensive accelerator specifically for pion therapy is described as is also the status of clinical trials using the existing Clinton P. Anderson Meson Physics Facility. The advantages of proton over electron accelerator for the production of high quality, high intensity negative pion beams suitable for radiation therapy of malignancies is also addressed. Other current, medically related applications of LAMPF technology are also discussed

No abstract available

[en] The main vehicle for bringing the pion to bear on a vast array of problems, has been the meson factories. Today there exist such facilities in Switzerland (SIN), in Canada (TRIUMF), and in the USA (LAMPF). A fourth is just now being completed in the Soviet Union. They are enormous enterprises - the current replacement value of LMPF is $350 million, not including the part devoted to national security problems. But they accommodate hundreds of scientists from around the world and by so doing generate political as well as intellectual and economic capital. Proton facilities, together with heavy-ion accelerators and electron facilities, form a triad on which stands the present edifice of experimental nuclear science. Each leg of this triad is dependent, to a greater or lesser extent, on the other two. However, in terms of versatility, the size of the community it serves, and the relatively short-term application of the knowledge base and people base for which nuclear science is responsible, the meson factory part of the above triad is by no means the least important component. I discuss this component from the standpoint of the facility I know best, namely LAMPF. 33 refs., 36 figs

[en] The status of the last year are reviewed. Topics covered include some major research advances, eg. muon decay, major facilities additions and operational milestones. Also discussed are the politics of LAMPF II and management issues

No abstract available

No abstract available

[en] Crucial aspects of the LAMPF operation and its scientific programs during 1978 are discussed and evaluated. This report is from a talk given at the Twelfth LAMPF Users Meeting, Novermber 13 and 14, 1978

No abstract available

No abstract available